ClinicalTrials.gg

Program

UTAA91

A development code. Also written as “UTAA91 injection”.

Its studies are mostly in Scleroderma, Systemic · Arthritis, Rheumatoid · Lupus Erythematosus, Systemic, led by PersonGen BioTherapeutics (Suzhou).

Furthest: early phase 1, since May 6, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PersonGen BioTherapeutics (Suzhou)33 open or runningearly phase 1since May 6, 2025May 6, 2025Dec 2027early phase 1 · NCT06982534

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2025First studies: 3 early phase 1 studiesFirst studyNCT06970951, NCT06982547, NCT06982534

Ahead

  1. Dec 2027Primary completion: early phase 1 study in Arthritis, RheumatoidNCT06982547
  2. Dec 2027Primary completion: early phase 1 study in Scleroderma, SystemicNCT06982534

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06982547Arthritis, Rheumatoid · ChinaEarly 1Not yet recruitingDec 202724
NCT06982534Scleroderma, Systemic · ChinaEarly 1Not yet recruitingDec 202724
NCT06970951Lupus Erythematosus, Systemic · ChinaEarly 1Not yet recruitingJun 30, 202615

How it is read

Names in the registry

  • “UTAA91 injection”, 3 entries

Codes read as this program: UTAA91.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.